首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3 12 and 30 milligrams per kilogram of body weight to healthy male volunteers.
【2h】

Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3 12 and 30 milligrams per kilogram of body weight to healthy male volunteers.

机译:替考拉宁对健康男性志愿者静脉内给予每公斤体重3、12​​和30毫克的替考拉宁的药代动力学。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Teicoplanin pharmacokinetics were evaluated after multiple-dose intravenous administration to healthy male volunteers by using a randomized, double-blind, parallel design. Doses of 3, 12, or 30 mg of teicoplanin per kg of body weight were administered every 24 h for 14 days as 60-min constant-rate intravenous infusions. Blood and urine samples were collected over 21 days and analyzed by a microbiological assay. Twenty-three subjects were included in the pharmacokinetic analysis. The median pharmacokinetic parameters upon multiple-dose intravenous administration of 3, 12, and 30 mg/kg included steady-state volumes of distribution of 0.94, 0.77, and 0.68 liter/kg; total clearances of 11.9, 12.0, and 13.2 ml/h/kg; and terminal disposition half-lives of 143, 166, and 96 h, respectively. Renal clearance accounted for approximately 95% of total clearance. No dose-related differences existed for teicoplanin total or renal clearance. The steady-state volume of distribution decreased significantly with increasing doses. As a result of the decrease in the volume of distribution, the terminal disposition half-life at 30 mg/kg was significantly decreased. However, the decreases in the volume of distribution and terminal disposition half-life are of limited clinical importance, since steady-state trough concentrations in serum increase in proportion to dose. Combined results of all multiple-dose studies with similar durations of sample collection indicate no dose-related differences for any pharmacokinetic parameters from 3 to 12 mg/kg. As observed in the present study, no dose-related differences exist for teicoplanin total and renal clearances from 3 to 30 mg/kg. However, at 30 mg/kg, a significant decrease in the steady-state volume of distribution is observed. As a consequence of the reduction in the volume of distribution at 30 mg/kg with no change in clearance, the terminal disposition half-life is decreased.
机译:通过使用随机,双盲,平行设计对健康男性志愿者进行多剂量静脉内给药后,评估替考拉宁的药代动力学。每24小时以60分钟恒定速率静脉内输注的剂量每3公斤,每公斤体重3、12​​或30毫克替考拉宁给药。在21天内收集血液和尿液样品,并通过微生物分析进行分析。二十三个受试者包括在药代动力学分析中。静脉内给药3、12和30 mg / kg时的中位药代动力学参数包括稳态体积分布0.94、0.77和0.68升/ kg;总间隙为11.9、12.0和13.2 ml / h / kg;和终端处置半衰期分别为143、166和96小时。肾脏清除率约占总清除率的95%。替考拉宁总清除率或肾清除率不存在剂量相关的差异。随着剂量的增加,稳态分布体积显着下降。由于分布体积的减少,在30 mg / kg时的最终处置半衰期显着降低。但是,分布体积的减少和终末处置半衰期的临床重要性有限,因为血清中的稳态谷浓度与剂量成正比。所有多剂量研究与相似采样时间的合并结果表明,对于3至12 mg / kg的任何药代动力学参数,没有剂量相关的差异。正如本研究中所观察到的,替考拉宁总和肾清除率从3至30 mg / kg不存在剂量相关的差异。但是,在30 mg / kg时,观察到稳态分布体积显着下降。由于在30 mg / kg的情况下分配体积的减少而清除率没有变化,因此最终的处置半衰期降低了。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号